Solid Power stock falls after $130 million registered direct offering

Investing.com -- AlphaTON Capital Corp. (NASDAQ:ATON) stock jumped 19.6% on Wednesday after the company announced its leadership team presented at President Donald Trump’s Mar-a-Lago Club in Palm Beach, Florida.

The private, invitation-only investor gathering on January 27, 2026, brought together high-net-worth investors, family offices, and strategic capital partners. During the presentation, AlphaTON shared insights into its infrastructure expansion initiatives, strategic acquisitions, and growth strategy within the TON blockchain ecosystem.

AlphaTON positions itself as a public-market gateway to the TON ecosystem, which leverages Telegram’s global user base. The company builds TON-based infrastructure, operates validator systems, manages a TON token reserve, and invests in decentralized applications across finance, gaming, and digital commerce.

The company recently raised net $44 million in capital and is generating revenue from AI infrastructure deployments. AlphaTON closed a $15 million registered direct offering at $1.00 per share and initiated a $46 million investment in AI infrastructure expansion, including 576 NVIDIA B300 chips scheduled for delivery in March 2026.

"Our mission is to build the infrastructure and applications that will power the next generation of the digital economy," said Enzo Villani, Executive Chairman and CIO of AlphaTON Capital. "Presenting at President Trump’s Mar-a-Lago Club allowed us to engage directly with a sophisticated group of investors who recognize the scale and momentum of the TON ecosystem."

The company has also established strategic partnerships, including becoming a Founding Federated Node Architecture Provider for privacy-preserving AI through an agreement with Midnight Foundation, which generates monthly revenue.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- OKYO Pharma Limited (NASDAQ:OKYO) stock climbed 4.7% Wednesday after the company announced successful discussions with the FDA regarding its Phase 2b/3 clinical trial design for urcosimod, a treatment for neuropathic corneal pain (NCP).

The London and New York-based biopharmaceutical company received confirmation from the FDA that its proposed primary endpoint of Visual Analogue Scale pain reduction at Week 12 is clinically meaningful. The agency specifically acknowledged that a 2-point or greater improvement on the VAS scale represents a meaningful treatment effect.

The FDA also endorsed OKYO’s proposed study design, sample size, and powering assumptions, while agreeing that the Ocular Pain Assessment Survey is appropriate as supportive quality-of-life evidence. Additionally, the agency aligned with the company’s Chemistry, Manufacturing and Controls strategy.

"This alignment represents an important step forward and underscores the potential to address a significant unmet medical need in patients with neuropathic corneal pain," said Raj Patil, Chief Scientific Officer at OKYO Pharma.

The company plans to initiate a 120-patient Phase 2b/3 multiple-dose study of urcosimod to treat NCP in the first half of this year. Urcosimod previously received fast track designation from the FDA and was granted the first Investigational New Drug application to treat patients with NCP.

OKYO Pharma focuses on developing therapies for the treatment of neuropathic corneal pain and inflammatory eye diseases.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.